{
  "paper_metadata": {
    "pmid": "25395306",
    "title": "Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage",
    "extraction_summary": "Extracted information on TTR variants V122I and T119M, including clinical significance, penetrance data, and functional studies."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.122G>A",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 10,
        "demographics": "4% of African\u2013Americans",
        "phenotype": "late onset familial amyloid cardiomyopathy (FAC), resulting in congestive heart failure and death"
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "congestive heart failure",
          "evidence_sentence": "The most common TTR mutation worldwide is V122I which is found in 4% of African\u2013Americans and produces late onset FAC, resulting in congestive heart failure and death."
        }
      ],
      "functional_data": {
        "summary": "V122I TTR variant is cytotoxic to human cardiac cells, generating superoxide species and activating caspase 3/7.",
        "assays": [
          "cell viability assays",
          "caspase activation assays"
        ]
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "4% in African\u2013Americans",
      "evidence_level": "strong evidence for pathogenicity",
      "source_location": "Introduction, paragraph 4",
      "additional_notes": "V122I TTR is associated with significant cytotoxic effects in cardiomyocytes.",
      "key_quotes": [
        "V122I TTR variant is cytotoxic to human cardiac cells.",
        "Incubation of the human cardiomyocytes with V122I TTR but not with T119M TTR, generates superoxide species and activates caspase 3/7."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.118A>C",
      "protein_notation": "p.Thr119Met",
      "genomic_position": null,
      "clinical_significance": "benign",
      "patients": {
        "count": 10,
        "demographics": null,
        "phenotype": "non-amyloidogenic variant, does not induce cytotoxicity"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "T119M TTR variant is stable and non-amyloidogenic, does not induce cytotoxicity in cardiomyocytes.",
        "assays": [
          "cell viability assays"
        ]
      },
      "segregation_data": "Does not segregate with disease.",
      "population_frequency": null,
      "evidence_level": "evidence suggests benign nature",
      "source_location": "Introduction, paragraph 4",
      "additional_notes": "T119M TTR is used as a control in functional studies.",
      "key_quotes": [
        "the stable and non-amyloidogenic T119M TTR variant does not have such effects."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data extracted from the main text."
  }
}